This is the definitive drug development forum for research teams to investigate how to modulate the cGAS-STING and Toll-like receptor (7/8/9) pathways both as monotherapies and as
The American Society for Hematology congress was dominated by CAR-T therapies – their potential new uses, how to manage safety issues and bring these costly cellular treatments to patients.